OmidHamidMD
Oncology • Santa Monica, CAHematologic Oncology, Melanoma, Complementary and Integrative
Chief, Reasearch & Immuno-Oncology
Dr. Hamid is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2001 Santa Monica Blvd
Ste 560W
Santa Monica, CA 90404Phone+1 310-582-7900Fax+1 310-582-7946
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2004 - 2005- University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2003 - 2004
- University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2002 - 2003
- University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1999 - 2002
Keck School of Medicine of the University of Southern CaliforniaClass of 1999
Certifications & Licensure
CA State Medical License 2001 - 2026
Clinical Trials
- Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma Start of enrollment: 2010 Jun 22
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
- A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
- Join now to see all
Publications & Presentations
PubMed
- 2357 citationsGuidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaAxel Hoos, Steven J. O'Day, Jeffrey S. Weber, Omid Hamid, Céleste Lebbé
Clinical Cancer Research. 2009-12-01 - 817 citationsCombined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.Hussein Abdul-Hassan Tawbi, Peter A. Forsyth, Alain Algazi, Omid Hamid, F. Stephen Hodi
The New England Journal of Medicine. 2018-08-22 - 600 citationsAn immune-active tumor microenvironment favors clinical response to ipilimumabRui-Ru Ji, Scott D. Chasalow, Lisu Wang, Omid Hamid, Henrik Schmidt
Cancer Immunology, Immunotherapy. 2012-07-01
Journal Articles
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainKim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
Other
- Mucosal melanomaHamid O, Ariyan C, Carvajal RD
http://www.uptodate.com/contents/mucosal-melanoma
UpToDate, Wolters Kluwer Health - 2012-06-11
Authored Content
- ESMO 2021: Leaving Paris Energized to Return to Patient CareSeptember 2021
Press Mentions
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D DayJuly 25th, 2024- Getting Under the Skin at May 11 Symposium on MelanomaMay 1st, 2024
- Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (Cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient PopulationsMay 26th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
